Trials / Not Yet Recruiting
Not Yet RecruitingNCT07459647
A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
An Open-Label Study to Assess the Long-Term Safety, Tolerability, and Effectiveness of ML-007C-MA in Adult Participants With Schizophrenia
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 500 (estimated)
- Sponsor
- MapLight Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
ML-007C-MA-212 is a 52-week open-label study designed to evaluate the long-term safety, tolerability, and effectiveness of ML-007C-MA in participants with schizophrenia who have recently completed an antecedent study (ML-007C-MA-211) or enroll directly (De Novo Cohort).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ML-007C-MA | ML-007C-MA dosed as 210/3 mg BID |
Timeline
- Start date
- 2026-03-01
- Primary completion
- 2030-02-01
- Completion
- 2030-02-01
- First posted
- 2026-03-10
- Last updated
- 2026-03-10
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07459647. Inclusion in this directory is not an endorsement.